Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
A phase 1/2 trial of Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by PDC*line Pharma SAS, active and no longer recruiting.
Overview
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC is a phase 1/2 interventional study registered as NCT03970746 by PDC*line Pharma SAS, with 73 participants enrolled, started 2019-09-10 and due to reach its primary completion in 2024-07-18. Interventions recorded: PDC*lung01, Keytruda Injectable Product, Alimta Injectable Product. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.